New message board for VERU as of 10/15/17
About Veru Inc. Veru Inc. (Veru) is a biopharmaceutical company focused on urology and oncology. Veru utilizes FDA's 505(b)(2) regulatory approval pathway to develop and commercialize drug candidates. FDA's 505(b)(2) regulatory approval pathway is designed to allow for potentially expedited regulatory approval based on a previously established safety and efficacy profile of the product. Veru is developing products under the 505(b)(1) pathway as well, which is the traditional new drug application (NDA) pathway. The company is currently developing drug product candidates for benign prostatic hyperplasia (BPH or enlarged prostate), hot flashes associated with prostate cancer hormone treatment, male infertility and novel oral chemotherapy (alpha & beta tubulin inhibitor) for a variety of malignancies, including metastatic prostate, breast and ovarian cancers. In addition, the company markets and sells the FC2 Female Condom® (now available by prescription in the US) and PREBOOST® medicated individual wipe, which is a male genital desensitizing drug product for the prevention of premature ejaculation. The company’s division, The Female Health Company, is focused on the global public health sector FC2 business. This division markets the company’s Female Condom (FC2) to entities, including ministries of health, government health agencies, U.N. agencies, nonprofit organizations and commercial partners, that work to support and improve the lives, health and well-being of women around the world. More information about Veru and its products can be found at www.veruhealthcare.com, www.PREBOOST.com and www.fc2femalecondom.com. For corporate and investor-related information about the Company, please visit https://veruhealthcare.com/investors
Female Health Company (The) (NASDAQ:VERU) was upgraded by Zacks Investment Researchfrom a “hold” rating to a “buy” rating in a research report issued to clients and investors on Wednesday. The brokerage presently has a $2.50 target price on the stock.
According to Zacks, “Veru Inc. engages in the development, manufacture and marketing of consumer health care products. It focuses on producing FC2 female condom which provides dual protection against unintended pregnancy and sexually transmitted infections. Veru Inc., formerly known as The Female Health Company, is headquartered in Miami, FL. “
VERU has been the subject of several other research reports. ValuEngine upgraded shares of Female Health Company (The) from a “sell” rating to a “hold” rating in a research report on Thursday, August 31st. Rodman & Renshaw began coverage on shares of Female Health Company (The) in a research report on Wednesday, July 26th. They issued a “buy” rating and a $5.00 price target for the company. Finally, HC Wainwright set a $5.00 price target on shares of Female Health Company (The) and gave the company a “buy” rating in a research report on Wednesday, July 26th.
Shares of Female Health Company (NASDAQ VERU) traded up 4.40% on Wednesday, reaching $2.61. The company’s stock had a trading volume of 225,223 shares. Female Health Company has a 1-year low of $0.72 and a 1-year high of $2.70. The stock has a 50-day moving average of $1.38 and a 200 day moving average of $1.15.
Female Health Company (The) (NASDAQ:VERU) last issued its quarterly earnings results on Tuesday, August 8th. The company reported ($0.03) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.08) by $0.05. The business had revenue of $4.31 million during the quarter, compared to the consensus estimate of $2.20 million. Female Health Company (The) had a negative net margin of 42.02% and a negative return on equity of 16.78%. On average, equities analysts expect that Female Health Company will post ($0.17) EPS for the current year.
In related news, Director Harry Fisch bought 34,250 shares of the business’s stock in a transaction on Wednesday, September 13th. The stock was bought at an average price of $1.51 per share, for a total transaction of $51,717.50. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Mitchell Shuster Steiner bought 100,000 shares of the business’s stock in a transaction on Friday, September 15th. The stock was bought at an average price of $1.63 per share, with a total value of $163,000.00. Following the transaction, the insider now owns 7,764,767 shares in the company, valued at $12,656,570.21. The disclosure for this purchase can be found here. In the last quarter, insiders acquired 146,975 shares of company stock valued at $234,279. Insiders own 10.90% of the company’s stock.
Female Health Company (The) Company Profile
Veru Inc, formerly The Female Health Company, is a therapeutics company focused on developing and commercializing pharmaceuticals and devices in men’s and women’s health and oncology. The Company is engaged in the development, manufacture and marketing of consumer healthcare products. The Company has three divisions: Pharmaceutical and Devices, Consumer Health Products and Public Sector.